Get the Stockscreener App
2.91
8.18%
0.22
After Hours:
2.93
0.02
+0.69%
Anixa Biosciences Inc stock is traded at $2.91, with a volume of 596.18K.
It is up +8.18% in the last 24 hours and up +5.43% over the past month.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
See More
Previous Close:
$2.69
Open:
$2.76
24h Volume:
596.18K
Relative Volume:
4.76
Market Cap:
$99.01M
Revenue:
$210.00K
Net Income/Loss:
$-10.40M
P/E Ratio:
-9.241
EPS:
-0.3149
Net Cash Flow:
$-6.88M
1W Performance:
+17.34%
1M Performance:
+5.43%
6M Performance:
-10.19%
1Y Performance:
-18.03%
1-Day Range:
$2.58
$2.94
1-Week Range:
$2.41
$2.94
52-Week Range:
$2.32
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.91 | 91.52M | 210.00K | -10.40M | -6.88M | -0.3149 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Maxim Group | Buy |
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Anixa Biosciences Inc (ANIX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Anixa Biosciences Inc (ANIX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Anixa Biosciences Inc (ANIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Penny Stocks To Watch For Growth In June 2026 - simplywall.st
Anixa Biosciences Inc (ANIX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Anixa Biosciences Inc (ANIX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Anixa Biosciences Inc (ANIX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Insider Buying: Titterton Lewis H Jr Increases Stake in Anixa Bi - GuruFocus
Anixa Biosciences (ANIX) director adds 2,836 shares in open-market buy - Stock Titan
Anixa Biosciences Inc (ANIX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Anixa Biosciences Gains Over 5% as Biotech Sector Shows Renewed Interest (ANIX)OBV Trend Line - newsline.com
CEO Amit Kumar Increases Stake in Anixa Biosciences Inc - GuruFocus
Anixa Biosciences CEO Amit Kumar buys $52,500 in company stock By Investing.com - Investing.com India
Anixa Biosciences (NASDAQ: ANIX) CEO adds 21,000 shares - Stock Titan
Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer C - GuruFocus
12 Health Care Stocks Moving In Monday's After-Market SessionAlvotech (NASDAQ:ALVO), Anixa Biosciences - Benzinga
ANIX Q1 2026 Earnings: Narrower-than-expected loss highlights disciplined spending amid clinical developmentGuidance Update - newsline.com
Anixa Biosciences (ANIX) Holds Near Key Support After Marginal DeclineRisk Reversal - newsline.com
H.C. Wainwright reiterates Buy on Anixa stock, $7 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy on Anixa stock, $7 target - Investing.com
Anixa Biosciences Announces Presentations of Two Clinical-Stage - GuruFocus
Anixa Biosciences, Inc. (ANIX) Stock Price, News, Quote & History - Yahoo Finance
Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium - PR Newswire
ANIX SEC FilingsAnixa Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Anixa Biosciences Inc 3Q 2026: Net loss $(2.52M), EPS $(0.07) — 10-Q Summary - TradingView
Anixa Biosciences (NASDAQ: ANIX) trims losses and details cancer pipeline - Stock Titan
Number of shareholders of Anixa Biosciences, Inc. – GETTEX:CY71 - TradingView
Anixa Biosciences Holds Steady Near Support as Trading Volume Remains SubduedSuperTrend - The Legal Advocate
Anixa Biosciences (ANIX) Secures Patent for Ovarian Cancer Vacci - GuruFocus
Anixa Biosciences (ANIX) Secures Patent for Ovarian Cancer Vaccine Technology - GuruFocus
Anixa receives Canadian patent allowance for ovarian cancer vaccine By Investing.com - Investing.com Nigeria
Anixa receives Canadian patent allowance for ovarian cancer vaccine - Investing.com
Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance - PR Newswire
Anixa Biosciences (ANIX) Edges Higher, Tests Key Support ZoneQuality Factor - The Legal Advocate
Anixa Biosciences (ANIX) Holds Steady at $2.73 as Consolidation ContinuesMomentum ETF - The Legal Advocate
Anixa Biosciences (ANIX) Slides 2.15% as Biotech Sector Headwinds ReturnPrice Action Signals - The Legal Advocate
Anixa Biosciences (ANIX) Edges Higher on Above-Average Volume, Testing Key ResistanceGap and Go - newsline.com
Anixa Biosciences Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
ANIX Stock Price, Quote & Chart | ANIXA BIOSCIENCES INC (NASDAQ:ANIX) - ChartMill
Anixa Biosciences Issues Correction to May 11, 2026 Announcement, Details Available on StockTitan.net - geneonline.com
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-Cel Ovarian Cancer Car-T Therapy - marketscreener.com
Anixa Biosciences (ANIX) Reports Promising Survival Data from Cl - GuruFocus
Anixa reports survival data from ovarian cancer therapy trial - Investing.com UK
/C O R R E C T I O N -- Anixa Biosciences, Inc./ - PR Newswire
Anixa reports survival data from ovarian cancer therapy trial By Investing.com - Investing.com Australia
Anixa Biosciences Reports Updated Positive Survival Observations From Ongoing Phase 1 Trial Of Lira-Cel Ovarian Cancer CAR-T Therapy - TradingView
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy - StreetInsider
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer - Quantisnow
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat - Quantisnow
Anixa Biosciences (NASDAQ:ANIX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV - The Malaysian Reserve
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):